AUTOLOGUS MARROW TRANSPLANTATION

本提案的具体目的是评估 自体骨髓移植（AMT）治疗急性白血病患者， 恶性淋巴瘤 既往试验的移植前治疗方案或 在我们的同基因和同种异体项目中进行测试的药物将与AMT一起使用 为了比较不同类型的复发率， 骨髓。 长期目标是确定是否自体 骨髓可以成功地用作同基因或 没有合适供体的患者的同种异体骨髓。 我们将 评估移植后化疗的效果和 用单克隆抗体预防移植后复发。

The specific aims of this proposal are to evaluate the effectiveness of autologous marrow transplantation (AMT) in patients with acute leukemia and malignant lymphoma. Pretranplant treatment regimens previously tested or being tested in our syngeneic and allogeneic programs will be used with AMT in order to allow comparisons of the relapse rate using the different tupes of marrow. The long-term goal is to ascertain whether or not autologous marrow can be used successfully as an alternative to syngeneic or allogeneic marrow in patients who do not have suitable donors. We will evaluate the effects of posttransplant chemotherapy and the incubation of marrow with monoclonal antibodies in preventing posttransplant relapses.